المؤلفون: Rivera FB; Department of Medicine, Lincoln Medical Center, New York, New York, USA., Lumbang GNO; Cebu Institute of Medicine, Cebu City, Philippines., Gaid DRM; Cebu Institute of Medicine, Cebu City, Philippines., Cruz LLA; University of the Philippines College of Medicine, Manila, Philippines., Magalong JV; University of the Philippines College of Medicine, Manila, Philippines., Bantayan NRB; University of the Philippines College of Medicine, Manila, Philippines., Lara-Breitinger KM; Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA., Gulati M; Department of Cardiology, Barbra Streisand Women's Heart Center, Cedars-Sinai Smidt Heart Institute, Los Angeles, California, USA., Bakris G; Department of Medicine, University of Chicago, Chicago, Illinois, USA.

المصدر: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2024 Jun; Vol. 26 (6), pp. 2209-2228. Date of Electronic Publication: 2024 Mar 20.

نوع المنشور: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE

مواضيع طبية MeSH: Glucagon-Like Peptide-1 Receptor*/agonists , Blood Pressure*/drug effects , Hypoglycemic Agents*/therapeutic use , Diabetes Mellitus, Type 2*/drug therapy , Diabetes Mellitus, Type 2*/complications , Diabetes Mellitus, Type 2*/blood, Humans ; Randomized Controlled Trials as Topic ; Liraglutide/therapeutic use ; Glucagon-Like Peptides/therapeutic use ; Glucagon-Like Peptides/analogs & derivatives ; Exenatide/therapeutic use ; Exenatide/pharmacology ; Immunoglobulin Fc Fragments/therapeutic use ; Recombinant Fusion Proteins/therapeutic use ; Glucagon-Like Peptide-1 Receptor Agonists